A Phase 3 interventional study of Dapagliflozin and Dapagliflozin placebo in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 42 sites in 7 countries. Open to participants aged 10 Years to 24 Years. Per ClinicalTrials.gov, last updated 2022-02-23.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 95th largest by enrollment, is one of 19 that started in 2016, is one of 47 in phase 3, and was the 79th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 10 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 19 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 173rd largest by enrollment of the 280 interventional ones that give a count, is one of 12 that started in 2016, is one of 119 in phase 3, and was the 261st registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study:
Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening.
Use of prescription or non-prescription weight loss drugs must be stable during the study
Replacement or chronic systemic therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit.
Note: Topical, nasal, or inhaled corticosteroids are allowed
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dapagliflozin
Drug: Dapagliflozin placebo
Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
Also known as: FORXIGA
matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24
Time frame: Baseline to Week 24
Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Time frame: Baseline to Week 24
Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control
Time frame: Baseline to Week 24
Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24
Time frame: Baseline to Week 24
Participants took part in the study at 42 study centres in 7 countries worldwide.
| Milestone | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Started | 39 | 33 |
| Received treatment | 39 | 33 |
| Completed | 34 | 27 |
| Not completed | 5 | 6 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Withdrawal by parent/guardian | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Milestone | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Started | 33 | 27 |
| Completed | 32 | 24 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Percentage of HbA1c | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24 | -0.25 ± 0.30 | 0.50 ± 0.34 |
| mmol/L | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -0.07 ± 0.53 | 0.72 ± 0.61 |
| Percentage of participants | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control | 5.1 | 9.1 |
| Percentage of participants | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24 | 25.0 | 4.2 |
Collected over Up to a maximum of 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 10mg/ Dapagliflozin 10mg | 0/39 (0%) | 2/39 (5.1%) | 24/39 (61.5%) |
| Placebo/ Dapagliflozin 10mg | 0/33 (0%) | 3/33 (9.1%) | 19/33 (57.6%) |
| Event | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 0/39 | 2/33 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/39 | 1/33 |
| Abdominal pain lowerGastrointestinal disorders | 1/39 | 0/33 |
| DepressionPsychiatric disorders | 1/39 | 0/33 |
| Event | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 5/39 | 2/33 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 5/39 | 2/33 |
| HeadacheNervous system disorders | 5/39 | 4/33 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/39 | 1/33 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/39 | 3/33 |
| NauseaGastrointestinal disorders | 3/39 | 0/33 |
| Urinary tract infectionInfections and infestations | 3/39 | 1/33 |
| DiarrhoeaGastrointestinal disorders | 2/39 | 2/33 |
| ToothacheGastrointestinal disorders | 1/39 | 2/33 |
| PharyngotonsillitisInfections and infestations | 0/39 | 2/33 |
| Age, Continuous(Years) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| Mean | 16.1 ± 3.3 | 16.2 ± 3.6 | 16.1 ± 3.4 |
| Age, Customized(Participants) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| ≥10 and ≤15 | 16 | 14 | 30 |
| >15 and <18 | 13 | 10 | 23 |
| ≥18 and <25 | 10 | 9 | 19 |
| Sex: Female, Male(Participants) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| Female | 24 | 19 | 43 |
| Male | 15 | 14 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 12 | 24 |
| Not Hispanic or Latino | 26 | 21 | 47 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| White | 28 | 16 | 44 |
| Black or African American | 8 | 10 | 18 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| American Indian or Alaska Native | 2 | 3 | 5 |
| Other | 0 | 3 | 3 |
| Geographic Region(Participants) | Dapagliflozin 10mg/ Dapagliflozin 10mg | Placebo/ Dapagliflozin 10mg | Total |
|---|---|---|---|
| North America | 16 | 16 | 32 |
| Latin America | 7 | 9 | 16 |
| Europe | 16 | 8 | 24 |
| Asia/Pacific | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2016 to primary completion in Apr 2020, 45 months.
Results were first posted in Dec 2020, 7 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 45 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin